The DOI matches its Crossref record; 415 of the 422 references it cites were found in a registry or an index.
Inflammation in obesity, diabetes, and related disorders
Open accessAbstract
Obesity leads to chronic, systemic inflammation and can lead to insulin resistance (IR), β-cell dysfunction, and ultimately type 2 diabetes (T2D). This chronic inflammatory state contributes to long-term complications of diabetes, including non-alcoholic fatty liver disease (NAFLD), retinopathy, cardiovascular disease, and nephropathy, and may underlie the association of type 2 diabetes with other conditions such as Alzheimer's disease, polycystic ovarian syndrome, gout, and rheumatoid arthritis. Here, we review the current understanding of the mechanisms underlying inflammation in obesity, T2D, and related disorders. We discuss how chronic tissue inflammation results in IR, impaired insulin secretion, glucose intolerance, and T2D and review the effect of inflammation on diabetic complications and on the relationship between T2D and other pathologies. In this context, we discuss current therapeutic options for the treatment of metabolic disease, advances in the clinic and the potential of immune-modulatory approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity further amplifies systemic inflammation, creating a self-perpetuating cycle that markedly increases the risk of cardiovascular disease and diabetes [38].”
From Navigating the potential of algal peptides: health effects, market applications, and scientific challenges (2026) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, inflammatory cytokines such as IL-1β and tumor necrosis factor alpha (TNF-α), abundant in the AD brain, suppress GLUT expression, while oxidative stress further destabilizes and inactivates transporter proteins.”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [73]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inflammation, as a basic pathological process, is critically implicated in the pathogenesis and progression of numerous diseases.”
From Picroside II as a Potential Anti-Inflammatory Agent (2026) · cites this paper as [5]
In the citing paper
“Our data using Cd68-eGFP mice support previous findings that obesity is associated with chronic inflammation37, as we observed increased expression numbers of Cd68-eGFP+ cells throughout the mouse.”
From A deep-learning framework reveals whole-body perturbations at cell level (2026) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–415 of 415
Ruscitti, P., Ursini, F., Cipriani, P., Liakouli, V., Carubbi, F., Berardicurti, O., Sarro, G. D., & Giacomelli, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181203 · Cited by 45
IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial
Ebrahimi, F., Urwyler, S. A., Straumann, S., Doerpfeld, S., Bernasconi, L., Neyer, P. J., Schüetz, P., Müeller, B., Donath, M. Y., & Christ‐Crain, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00739 · Cited by 43
Self-citationFat fuels insulin resistance through Toll-like receptors
Tschöp, M. H., & Thomas, G. (2006) · Nature Medicine · doi:10.1038/nm1206-1359 · Cited by 42
Yazdani‐Biuki, B., Mueller, T., Brezinschek, H. P., Hermann, J., Graninger, W. B., & Wascher, T. C. (2006) · Diabetes Care · doi:10.2337/dc06-0636 · Cited by 41
Dash, P. K., & Moore, A. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1372 · Cited by 40
Activity-induced GLP-1 release in lean and obese subjects
Adam, T. C., & Westerterp‐Plantenga, M. S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.035 · Cited by 39
Ma, J., Wu, H., Zhao, C. Y., Panchapakesan, U., Pollock, C. A., & Chadban, S. J. (2014) · Europe PMC (PubMed Central) · Cited by 38
Nakano, Y., Chayama, K., Ochi, H., Toshishige, M., Hayashida, Y., Miki, D., Hayes, C. N., Suzuki, H., Tokuyama, T., Oda, N., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003364 · Cited by 38
Infliximab in the Treatment of Crohn Disease and Type 1 Diabetes
Timper, K., Hruz, P. L., Beglinger, C., & Donath, M. Y. (2013) · Diabetes Care · doi:10.2337/dc13-0199 · Cited by 36
Self-citationInterleukin-1 stimulates aldosterone secretion: involvement of renin, ACTH, and prostaglandins
Bataillard, A., del Rey, A., Klusman, I., MONGE‐ARDITI, G., & Besedovsky, H. O. (1992) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1992.263.4.r840 · Cited by 31
Kol, S., Ruutiainen-Altman, K., Scherzer, W. J., Ben‐Shlomo, I., Ando, M., Rohan, R. M., & Adashi, E. Y. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00260-3 · Cited by 27
Choi, B. S.-Y., Daoust, L., Pilon, G., Marette, A., & Tremblay, A. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0618-3 · Cited by 20
The role of IL-1 in postprandial fatigue
Lehrskov, L. L., Dorph, E., Widmer, A. M., Hepprich, M., Siegenthaler, J., Timper, K., & Donath, M. Y. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.04.001 · Cited by 19
Self-citationType 2 diabetes and psoriasis: links and risks
Holm, J. G., & Thomsen, S. F. (2019) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 12
Targeting Intestinal Macrophages as a Potential Therapeutic Option in Obesity
Rohm, T. V., AlAsfoor, S., Bosch, A. J. T., & Cavelti‐Weder, C. (2018) · Diabetes · doi:10.2337/db18-283-or · Cited by 4
Self-citation
Flagged first, then by citations
7 of the 422 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Ebstein, 1876, Zur Therapie des Diabetes Mellitus, insbesondere über die Anwendung des Salicylsauren Natron bei demselben, Berliner Klinische Wochenschrift., 24, 337
- Jonsson, 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1568
- Klover, 2003, Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice, Diabetes, 52, 2784, 10.2337/diabetes.52.11.2784 · DOI · Paper page
- Rohm, 2017, Increased Inflammatory Intestinal Macrophage Subpopulations after High-Fat Diet, Diabetes, 66, 51
Cited by
Sorted by citations
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Metformin: update on mechanisms of action and repurposing potential
Foretz, M., Guigas, B., & Viollet, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00833-4 · Cited by 791
Pathophysiology of obesity and its associated diseases
Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C. G., & Jiang, T. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.012 · Cited by 603
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 489
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
Tryphena, K. P., Shukla, R., Khatri, D. K., & Vora, L. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102481 · Cited by 438
Metadata
- Authors
- Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y.
- Affiliations
- University of California San Diego (US)
- University of Basel (CH)
- Corresponding author
- Donath, Marc Y.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 55
- Issue
- 1
- Pages
- 31-55
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC8773457
- OpenAlex
- W4206799195
- Cited by
- 2,066
- References
- 422
- Citations by year
- 2026: 450 · 2025: 649 · 2024: 512 · 2023: 345 · 2022: 108
- FWCI
- 64.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK063491, DK101395)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_200177)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
- Keywords
- obesity, type 2 diabetes, chronic inflammation, insulin resistance, beta-cell dysfunction, insulin secretion, impaired glucose tolerance, non-alcoholic fatty liver disease, diabetes complications, Alzheimer's disease, polycystic ovary syndrome, gout, rheumatoid arthritis, cardiovascular disease, kidney disease, retinopathy, immunomodulatory therapy, metabolic disease treatment
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Inflammation, Insulin Resistance, Obesity, Diabetes Complications, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
